Oramed Pharmaceuticals Inc. entered into a Supplemental Agreement to amend a Joint Venture Agreement with Hefei Tianhui Biotech Co., Ltd. for the creation of a new company, Oramed NewCo, which will focus on developing and distributing products, with an initial investment of $40 million from HTIT and $7.5 million from Oramed, and plans for a spin-off of shares to existing shareholders.